Table 1.

Gender-based prevalence of NAFLD in the general population

Author Year	Country	Population screened	Male prevalence*	Female prevalence**	Other findings
Butt et al.12 2011	Pakistan	163 patients with T2DM and MS	51.3%	40.7%	Overall NAFLD prevalence–72.4%. Prevalence was higher in patients with metabolic risk factors.
Eguchi et al.13 2012	Japan	5,075 subjects from the general population (2,448 female/2,627 male)	41%	18%	Positive linear relationship seen between BMI, LDL cholesterol, TG levels, and NAFLD prevalence.
Kalra et al.14 2013	India	924 T2DM patients (355 female/569 male)	54.3%	60%	Highest prevalence in the 61–70-year age-group.
Alam et al.15 2018	Bangladesh	2,782 participants from general population	33.82%	33.91%	Highest prevalence among females was seen in rural participants of 45–54 years. Higher risk identified in people with higher BMI, middle-aged adults and diabetics.
Park et al.16 2006	Korea	6,648 subjects from the general population (3,118 females/3,530 males)	21.6%	11.2%	Metabolic risk factors were significantly associated in both genders. Estrogen use and postmenopausal status were risk factors in women only.
Wong et al.17 2012	China	922 subjects from the general population (533 females/389 males)	37%	23%	Overall NAFLD prevalence–27.3%. In women, the prevalence increased after menopause.
Li et al.18 2014	China	3,56,367 subjects from the general population (1,52,124 females/2,01,481 males)	25%	13%	The prevalence of NAFLD increased with age up to 60 years.
Caballería et al.19 2010	Spain	766 subjects from the general population (443 females/323 males)	33%	20%	The factors associated with NAFLD were male sex, age, insulin resistance, ALT levels, and MS.

^*Among total males in study;

^**Among total females in study;

ALT, alanine aminotransferase; LDL, low-density lipoprotein; MS, metabolic syndrome; T2DM, type 2 diabetes mellitus; TG, triglyceride